Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment
Revista de Neurología · 2025-07-23 · 80 (6)
DOI: 10.31083/rn33482 ↗At a glance
Journal article in Revista de Neurología, published online on 2025-07-23. Written by Nuria García-Agua Soler and 2 co-authors. Institution: Economía de la Salud y Uso Racional de Medicamentos, Departamento de Farmacología, Facultad de Medicina, 29010 Málaga, España. Major MEDLINE topics: Parkinson Disease, Antiparkinson Agents, Quality of Life. Cited 2 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
As Parkinson’s disease progresses, symptoms develop that make it more difficult to control, either because of the presence of fluctuations despite adequate oral treatment, or because of the adverse effects caused by the continued use of levodopa, considered the gold standard. At this point in the course of the disease, there are different therapeutic alternatives that provide more continuous dopaminergic stimulation and help to improve this symptomatology: deep brain stimulation (Medtronic®: Percept™ Primary Cell (PC), Percept™ ReChargable (RC)), intestinal gel Levodopa/Carbidopa (Duodopa®) o Levodopa/Carbidopa/Entacapona (Lecigon®), as well as subcutaneous infusion of foslevodopa/foscarbidopa (Foslevodopa®) and continuous infusion of apomorphine (Dacepton®, Apo-Go®).
Objective
Pharmacoeconomic study of the different therapies for treating advanced Parkinson’s disease in Spain. Patients and Methods: Based on a Markov model, the efficacy and costs of these therapies were compared, measuring life years gained (LYG) and quality-adjusted life years (QALY).
Results
Dacepton® (apomorphine) is the most cost-effective option with a cost of 20,782€/QALY (1€ = 1.0815 USD, 2025), compared to three times or more for the other therapies with Lecigon® (levodopa/carbidopa/entacapone) being the least cost-effective with a cost of 104,000€/QALY. Deep brain stimulation (DBS) and Duodopa® also proved to be effective options, but more costly than Dacepton®.
Conclusions
These results provide additional information on the efficiency of treatments that should inform decision-making in the management of advanced Parkinson’s disease, thus enabling better resource management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Economía de la Salud y Uso Racional de Medicamentos, Departamento de Farmacología, Facultad de Medicina, 29010 Málaga, España.
- Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, 29016 Málaga, España.
- Servicio de Neurología, Hospital Regional Universitario de Málaga, 29010 Málaga, España.
Cite
APA
García-Agua Soler, N., García Trujillo, L., & García-Ruiz, A. J. (2025). Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment. Revista de Neurología, 80(6). https://doi.org/10.31083/rn33482
Vancouver
García-Agua Soler N, García Trujillo L, García-Ruiz AJ. Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment. Revista de Neurología. 2025;80(6). doi:10.31083/rn33482
BibTeX
@article{GarcaAguaSoler2025,
author = {García-Agua Soler, Nuria and García Trujillo, Lucía and García-Ruiz, Antonio J},
title = {Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment},
journal = {Revista de Neurología},
year = {2025},
volume = {80},
number = {6},
doi = {10.31083/rn33482}
}
EUVIMED